Ginkgo Bioworks Holdings, Inc. Logo

Ginkgo Bioworks Holdings, Inc.

A cell programming platform offering R&D services for pharma, agriculture, food, and chemicals.

DNA | US

Overview

Corporate Details

ISIN(s):
KYG8354H1267 (+2 more)
LEI:
Country:
United States of America
Address:
27 DRYDOCK AVENUE, 2210 BOSTON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ginkgo Bioworks Holdings, Inc. is a synthetic biology company that operates a leading horizontal platform for cell programming. Its core mission is to make biology easier to engineer, enabling customers to program cells with the ease of programming computers. The company's platform leverages high-throughput automation, proprietary software, artificial intelligence, and an extensive biological codebase to design, build, and test custom organisms for its partners. Ginkgo provides flexible, end-to-end R&D services to solve challenges across diverse markets, including pharmaceuticals, agriculture, food and nutrition, and specialty chemicals, facilitating the development of novel and more sustainable products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ginkgo Bioworks Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ginkgo Bioworks Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ginkgo Bioworks Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden
STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea
052020
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan
4599
Surrozen, Inc./DE Logo
Develops regenerative antibodies modulating the Wnt pathway to repair tissues and restore organs.
United States of America
SRZN
SyntekaBio,Inc. Logo
AI drug discovery platform accelerating R&D with supercomputing, SaaS, and pre-made candidates.
South Korea
226330
Tango Therapeutics, Inc. Logo
Developing precision oncology therapies for genetically-defined patients via synthetic lethality.
United States of America
TNGX
Taysha Gene Therapies, Inc. Logo
Developing AAV-based gene therapies for rare, severe monogenic diseases of the central nervous system.
United States of America
TSHA
Tectonic Therapeutic, Inc. Logo
Developing biologic therapies that modulate GPCRs for diseases with unmet needs.
United States of America
TECX
Telomir Pharmaceuticals, Inc. Logo
Developing an oral small molecule to reverse aging and treat age-related diseases.
United States of America
TELO
Tempest Therapeutics, Inc. Logo
Clinical-stage oncology company developing oral small molecule therapeutics to treat cancer.
United States of America
TPST

Talk to a Data Expert

Have a question? We'll get back to you promptly.